Customer Education

SMC Webinar

Custom Assay Development and Services utilizing Single Molecule Counting (SMC™) technology

 

 What Does it Cover?

Single molecule counting (SMC™) technology enables precise measurement of molecules at levels previously undetectable, down to the femtogram/mL levels, allowing researchers to identify new biomarkers, or assist in therapeutic development with an improved view of efficacy, safety & time course studies.   When time and resources are limited, MilliporeSigma offers a comprehensive portfolio of Custom Services supported by a scientific team with core expertise in SMC™ technology. Learn how our team will partner with you to develop a project specific to your requirements, whether that is fit-for-purpose sample testing, biomarker analysis using our current SMC™ immunoassays, or development and manufacture of an immunoassay for your novel target of interest.   Learn how we work with our clients to define and tailor a customized project plan that includes milestone driven tasks, collaborative data review and progress reports.   Whether your focus is to expedite your clinical research or to transfer a method to a CRO, we will show you how our services can help you accelerate programs from discovery into clinical trials. 

 

 What Will You Learn?

  • General background on Single Molecule Counting (SMC™) technology
  • How SMC technology enables quantification of low concentration biomarkers for improved stratification of sample populations, drug development and new biomarker discovery
  • Custom Assay & Sample Testing Services:  Discussion on full range of services available

 Who Should Attend?

  • Researchers interested in biomarker discovery
  • Therapeutic Development Scientists
  • Protein biochemists
  • Life science researchers
  • Molecular biologists

 

Speaker Bio
Sarah Hamren
Head of Custom Assays & Sample Testing
MilliporeSigma
Sarah J. Hamren has led the 10 member SMC™ Custom Assay and Sample Testing group since 2015; 7 team members report directly to Sarah. She has over 30 years of experience in biopharma research and development. Previously the Director of Assay Development of the Life Science Division for Singulex, Sarah has been responsible for the successful transfer to MilliporeSigma of the Singulex Life Science business unit, marketing, sales, manufacturing, quality control, accounts receivable, international reagent shipment, and customer support since its 2015 acquisition. Drawing on her past experience working with Chiron Corporation (now part of Novartis), Bayer Corporation’s Biotechnology division, Tethys Bioscience, Singulex, and now MilliporeSigma, maintaining the high-quality services clients expect from MilliporeSigma has been her constant goal. She is co-author on 15 peer-reviewed publications and holds 2 U.S. patents. Sarah’s 12 years of experience effectively partnering with a broad array of clients have culminated in 100s of successful biomarker assay development projects. She has proven success overcoming the limitations of challenging sample types and very small sample volumes while at the same time adhering to project deadlines, budgets, and the highest standards of quality control.